In our subsequent evaluation, which aimed to identify the mechanistic background of low DAPK expression in ovarian cancer cells, we used 5-Azacytidine, an antineoplastic nucleoside analog that functions as an epigenetic modifier by inhibiting DNA methyltransferase, to treat ovarian cancer cells. Here, DAPK1 is linked to ovarian carcinoma.